Filtered By:
Drug: Clarithromycin
This page shows you your search results in order of date.
Order by Relevance | Date
Total 15 results found since Jan 2013.
Low-Dose Colchicine for Secondary Prevention of Coronary Artery Disease: JACC Review Topic of the Week
J Am Coll Cardiol. 2023 Aug 15;82(7):648-660. doi: 10.1016/j.jacc.2023.05.055.ABSTRACTAmong statin-treated patients, inflammation assessed by means of high-sensitivity C-reactive protein (hsCRP) is a more powerful determinant of cardiovascular death and all-cause mortality than low-density-lipoprotein cholesterol (LDL-C). Several therapies that target residual inflammatory risk significantly reduce vascular event rates. For coronary artery disease patients already taking guideline-directed medical care, including statins, low-dose colchicine (0.5 mg/d orally) has been shown to safely lower major adverse cardiovascular even...
Source: Atherosclerosis - August 9, 2023 Category: Cardiology Authors: Kyle Nelson Valentin Fuster Paul M Ridker Source Type: research
Current status of drug repositioning in hematology
Expert Rev Hematol. 2021 Oct 16. doi: 10.1080/17474086.2021.1995348. Online ahead of print.ABSTRACTINTRODUCTION: Drug repositioning (DR) is defined as determining new therapeutic applications for existing drugs. This approach is advantageous over de novo drug discovery in accelerating clinical development, in terms of lower costs, a shortened development period, a well-known action mechanism, a feasible dosage, and an acceptable safety profile.AREAS COVERED: This work was aimed at reviewing agents with successful DR in hematology.EXPERT OPINION: Thalidomide and plerixafor have been successfully repositioned for treating mu...
Source: Expert Review of Hematology - October 18, 2021 Category: Hematology Authors: Akihiro Ohmoto Shigeo Fuji Source Type: research
Risk of mortality and cardiovascular events following macrolide prescription in chronic rhinosinusitis patients: a cohort study using linked primary care electronic health records.
CONCLUSIONS: Although not statistically significant, our best estimates suggest an increased short-term risk of myocardial infarction in patients with CRS following macrolide prescription, supporting previous observational evidence. However, confounding by indication remains a possible explanation for this apparent increased risk. We found no evidence of longer term increased risks.
PMID: 30928998 [PubMed - as supplied by publisher]
Source: Rhinology - April 2, 2019 Category: ENT & OMF Tags: Rhinology Source Type: research
Long-Term Risk of Acute Myocardial Infarction, Stroke, and Death With Outpatient Use of Clarithromycin: A Retrospective Cohort Study
AbstractIn a retrospective cohort study of patients enrolled in the UK Clinical Practice Research Datalink during 2000 –2013, we evaluated long-term risks of death, stroke, and acute myocardial infarction (AMI) in adults prescribed clarithromycin. Patients were outpatients aged 40–85 years, who were prescribed clarithromycin (n = 287,748), doxycycline (n = 267,729), or erythromycin (n = 442,999), orHelicobacter pylori eradication therapy with a proton pump inhibitor, amoxicillin, and either clarithromycin (n = 27,639) or metronidazole (n = 14,863). We analyzed time to death, stroke, or AMI with Cox proportional hazards...
Source: American Journal of Epidemiology - September 20, 2017 Category: Epidemiology Source Type: research
Managing Cardiovascular Risk of Macrolides: Systematic Review and Meta-Analysis
ConclusionsMore studies are required to investigate the short-term cardiovascular outcomes associated with different types of macrolides. Future studies are warranted to evaluate the effect of statins for preventing excess acute cardiovascular events associated with clarithromycin or other macrolides.
Source: Drug Safety - April 10, 2017 Category: Drugs & Pharmacology Source Type: research
Evaluation of the risk of cardiovascular events with clarithromycin using both propensity score and self‐controlled study designs.
ConclusionsThere was some evidence for a short term association for first MI but none for a long term association for any outcome.
Source: British Journal of Clinical Pharmacology - April 19, 2016 Category: Drugs & Pharmacology Authors: Adrian A. Root, Angel Y. S. Wong, Yonas Ghebremichael‐Weldeselassie, Liam Smeeth, Krishnan Bhaskaran, Stephen J. W. Evans, Ruth Brauer, Ian Chi Kei Wong, Vidya Navaratnam, Ian Douglas Tags: Pharmacoepidemiology Source Type: research
